Media Announcement

Posted 14/11/2006

Oncologists and haematologists are invited to participate in the live online forum Treating Early Hodgkin Lymphoma – Is Less More? at 7.30–9.00pm (AEDT) on Thursday 16 November 2006 as the sixth event in the 20:20 Oncologist Forum Series.

The forum will feature prominent oncologist Professor Volker Diehl, Chair, German Hodgkin Lymphoma Study Group and Director Emeritus, Department of Internal Medicine, University of Cologne, Germany.

Renowned for his pioneering research on Hodgkin Lymphoma, Professor Diehl will present the latest evidence for combination regimens using chemotherapy and radiotherapy to treat Early Hodgkin Lymphoma.

In a live panel discussion following the keynote presentation, leading Australian specialists will explore important topics such as the role of Positron Emission Tomography in influencing treatment decisions.

The panel will include:

• Associate Professor Joe McKendrick, Clinical Head, Medical Oncology, Haematology and Palliative Care, Eastern Health, Victoria (panel chair)
• Professor Kerry Taylor, Haematologist, Mater Adult Hospital, Mater Health Services, Brisbane
• Dr Andrew Wirth, Consultant Radiation Oncologist, Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne
• Dr Andrew Roberts, Clinical Haematologist, The Royal Melbourne Hospital, Parkville (questions moderator)

Participants can interact with panellists and colleagues in real time from their home or office by responding to polling questions or by submitting a question or comment to the panel via email.  

Register now at http://www.oncologistforum.com/ to participate in the forum and test your computer to ensure it is correctly set up to view the live event.

After registration, you can access the archived fora in the series about a range of topics including: the new generation of targeted therapies; treating advanced colorectal cancer; improving survival of patients with non-small cell lung cancer; hormonal management of adjuvant therapy in breast cancer; and intraperitoneal chemotherapy for the treatment of ovarian cancer.

The 20:20 Oncologist Forum is an innovative arena where oncologists and haematologists can debate, learn and share opinions on current issues and research, supported by an educational grant from Bristol-Myers Squibb as part of their ongoing commitment to oncology and haematology.

-ends-

Issued by Edelman BioScience Communications on behalf of Bristol-Myers Squibb.
For further information please contact:
Katie Perry, Account Manager, Edelman BioScience Communications on (02) 9291 3382